Vivos Therapeutics, Inc. (NASDAQ:VVOS) Receives $4.92 Average Price Target from Brokerages

Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) have earned a consensus rating of “Hold” from the five ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $4.9167.

Several equities research analysts recently commented on the company. HC Wainwright initiated coverage on Vivos Therapeutics in a report on Monday, November 17th. They set a “buy” rating and a $7.00 target price on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Wednesday, October 8th. Zacks Research upgraded shares of Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, December 1st. Finally, Ascendiant Capital Markets decreased their target price on shares of Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating for the company in a research note on Wednesday, December 3rd.

Vivos Therapeutics Stock Performance

NASDAQ:VVOS opened at $1.98 on Friday. The firm’s fifty day simple moving average is $2.44 and its 200 day simple moving average is $3.44. The company has a current ratio of 0.78, a quick ratio of 0.78 and a debt-to-equity ratio of 3.31. Vivos Therapeutics has a twelve month low of $1.93 and a twelve month high of $7.95. The firm has a market capitalization of $17.80 million, a price-to-earnings ratio of -1.12 and a beta of 6.88.

Vivos Therapeutics (NASDAQ:VVOS) last announced its quarterly earnings results on Wednesday, November 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.04. The firm had revenue of $6.78 million during the quarter, compared to the consensus estimate of $4.49 million. Vivos Therapeutics had a negative return on equity of 351.28% and a negative net margin of 98.77%. As a group, equities research analysts expect that Vivos Therapeutics will post -1.79 earnings per share for the current fiscal year.

Institutional Trading of Vivos Therapeutics

Several large investors have recently modified their holdings of VVOS. XTX Topco Ltd acquired a new position in shares of Vivos Therapeutics in the 2nd quarter valued at approximately $65,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Vivos Therapeutics in the second quarter worth $220,000. Finally, Connective Capital Management LLC bought a new stake in shares of Vivos Therapeutics in the third quarter worth $620,000. 26.35% of the stock is currently owned by institutional investors and hedge funds.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.